Celsus Therapeutics Strengthens Board of Directors With Addition of Dermatology Industry Veteran Robert F. Doman

Celsus Therapeutics Strengthens Board of Directors With Addition of Dermatology 
Industry Veteran Robert F. Doman 
NEW YORK, NY and LONDON -- (Marketwired) -- 05/01/13 --  Celsus
Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage
biotech company, announced the addition of industry veteran Robert F.
Doman to the Company's Board of Directors. 
"We are pleased that Bob has joined our board of directors," said Gur
Roshwalb, Chief Executive Officer of Celsus Therapeutics. "He brings
more than 30 years of international and domestic pharmaceutical and
medical leadership to the board, especially in the field of
dermatology, the focus of our lead asset in Phase II trials, MRX-6.
His business development, strategic planning and dermatology product
development skills will be valuable assets as we continue to advance
our portfolio of non-steroidal anti-inflammatory drugs." 
"I am pleased to be joining the Celsus board where I will have the
opportunity to work closely with management and the other board
members to create shareholder value," said Mr. Doman. "I look forward
to quickly contributing to the next stage in Celsus' growth by
helping to direct development of MRX-6 and advancing the current
pipeline of promising anti-inflammatory drugs." 
Mr. Doman is a seasoned pharmaceutical and medical device executive
with 30+ years of extensive international and domestic experience in
general management, business development, building sales and
marketing capabilities, new product development and strategic
planning. Most recently Bob served as President and Chief Executive
Officer of DUSA Pharmaceuticals, Inc., a publicly traded specialty
pharmaceutical and medical device company focused in the field of
dermatology. He joined DUSA in 2005 as President and Chief Operating
Officer and was promoted to President and Chief Executive Officer in
June 2007. DUSA was acquired by Sun Pharma in June of 2012. Prior to
joining DUSA Pharmaceuticals, Bob served as President of Leach
Technology Group, the medical electronic device, design, product
development and contract manufacturing services division of privately
held Leach Holding Corporation. From 1999 to 2000, Bob served as
President, Device Product Development of West Pharmaceutical
Services, a manufa
cturer of systems and device components for
parentally administered medicines and drugs. From 1991 to 1999, Bob
worked for the Convatec division of Bristol-Myers Squibb in positions
that included: Vice President, Worldwide Marketing and Business
Development; Vice President and General Manager, U.S. Wound and Skin
Care; and Vice President, U.S. Operations. 
Earlier in his career, Bob held sales, marketing and business
development roles of increasing responsibilities for Critikon, Inc.,
a Johnson and Johnson company. While serving as Business Director for
Vascular Access he licensed and launched the first Intravenous
Catheter with needle-stick protection, which is the industry standard
today. Bob currently serves as a member of the Board of Directors of
Echo Therapeutics, Inc. He received a Bachelor's degree from Saint
Joseph's University where he has served as a member of the
Development Committee and the Haub School of Business Advisory Board. 
About Celsus Therapeutics Plc. 
Celsus Therapeutics is an emerging clinical stage company focused on
the development of a new class of non-steroidal, synthetic
anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory
Drugs or MFAIDs. Celsus's MFAIDs represent a new therapeutic platform
for the treatment of a broad array of inflammatory diseases, such as
allergies and autoimmune diseases. Presently, the Company has two
lead drug candidates in its clinical pipeline, MRX-6, a topical cream
for contact dermatitis and MRX-4, a nasal spray for treating allergic
rhinitis (hay fever). Other potential treatments in preclinical
development include OPX-1 for ocular inflammation, CFX-1 for cystic
fibrosis, and MRX-5 for inflammatory bowel disease. 
FORWARD-LOOKING STATEMENTS - This press release contains
"forward-looking statements" that involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. In some cases, you can identify
forward-looking statements by terms including "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may,"
"plans," "potential," "predicts," "projects," "should," "will,"
"would," "hope," "look forward" and similar expressions intended to
identify forward-looking statements. Forward-looking statements
reflect our current views with respect to future events and are based
on assumptions and subject to risks and uncertainties. You should not
put undue reliance on any forward-looking statements. Unless we are
required to do so under applicable laws, we do not intend to update
or revise any forward-looking statements. 
Company Contact 
Celsus Therapeutics Plc. 
Gur Roshwalb, MD 
Chief Executive Officer 
gr@celsustx.com  
Investor Relations 
LifeSci Advisors, LLLC
Michael Rice
mrice@lifesciadvisors.com
646-597-6979